 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- A2B530 / A2 Biotherap
EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH) (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_974;
P=N/A, P1/
The primary objective of phase 1 is to evaluate the safety and tolerability of A2B530 in patients with NSCLC, CRC, and PANC, and to identify the maximum tolerated dose and recommended phase 2 dose (RP2D). The dose-expansion phase will confirm RP2D and collect biomarker data to further characterize A2B530.
- A2B694 / A2 Biotherap, A2B530 / A2 Biotherap
BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials (Ground Level - Exhibit Hall C - San Diego Convention Center) - Sep 27, 2023 - Abstract #SITC2023SITC_318;
P=N/A, P1/
We have identified 52 patients across sites with study-specific disease types with HLA-A*02:01 LOH; of these, 13 are currently being screened, 23 have been found ineligible, and 16 have consented. This demonstrated the feasibility of leveraging a diagnostic during routine clinical workup to identify rare, molecularly defined patients for personalized clinical studies.
- |||| A2B530 / A2 Biotherap
Clinical, Metastases: Investigators have initiated the BASECAMP-1 trial, w/ the hope of identifying pts w/ advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530. @mgfakih @cityofhope #oncology https://t.co/kNsfZiwPVR (Twitter) - May 2, 2023
- ||||| A2B530 / A2 Biotherap
Clinical, Metastases: Investigators have initiated the BASECAMP-1 trial, w/ the hope of identifying pts w/ advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530. @mgfakih @cityofhope #oncology https://t.co/1vr2JVzaqZ (Twitter) - Apr 29, 2023
- ||| A2B530 / A2 Biotherap
Enrollment open, CAR T-Cell Therapy, Metastases: EVEREST-1: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (clinicaltrials.gov) - Apr 26, 2023
P1/2, N=160, Recruiting, Sponsor: A2 Biotherapeutics Inc.
This demonstrated the feasibility of leveraging a diagnostic during routine clinical workup to identify rare, molecularly defined patients for personalized clinical studies. Not yet recruiting --> Recruiting
- |||| A2B530 / A2 Biotherap
New P1/2 trial, CAR T-Cell Therapy, Metastases: EVEREST-1: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (clinicaltrials.gov) - Feb 21, 2023
P1/2, N=160, Not yet recruiting, Sponsor: A2 Biotherapeutics Inc.
- A2B530 / A2 Biotherap
A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_566;
P=N/A
BASECAMP-1 ( NCT04981119 ), an observational study identifying patients with somatic HLA LOH, is recruiting. Eligible patients with metastatic colorectal, pancreatic, or non-small cell lung cancer will be apheresed for a future A2B530 EVEREST-1 interventional study.